Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Interferon-Activated Gene Stabilizes Proteins Linked to Breast Cancer Spread

By LabMedica International staff writers
Posted on 26 Jan 2012
The product of a gene activated by interferon blocks the breakdown of proteins that lead to cellular invasiveness, which may cause cancer cells to metastasize and spread beyond the site of the original tumor.

Interferon-stimulated gene 15 (ISG15) is an ubiquitin-like protein that becomes conjugated to many cellular proteins upon activation by interferon-alpha. More...
The pathway incorporating ISG15 activity is highly elevated in breast cancer, but how the ISG15 pathway contributes to breast tumorigenesis had not been studied to any great extent.

In the current study, using the gene disruption approach (gene knock-down), investigators at the Louisiana State University School of Medicine (New Orleans, USA) demonstrated that both ISG15 and UbcH8 (ISG15-specific conjugating enzyme) disrupted F-actin architecture and formation of focal adhesions in ZR-75-1 breast cancer cells. In addition, ISG15 and UbcH8 promoted breast cancer-cell migration. They also demonstrated that ISG15 inhibited ubiquitin/26S proteasome-mediated turnover of proteins implicated in tumor cell motility, invasion, and metastasis.

The results, which were published in the January 2012 issue of the journal Experimental Biology and Medicine, suggest that the aberrant activation of the ISG15 pathway confers a motile phenotype to breast cancer cells by disrupting cell architecture and stabilizing proteins involved in cell motility, invasion, and metastasis.

First author Dr. Shyamal Desai, assistant professor of biochemistry and molecular biology at the Louisiana State University School of Medicine, said, “Using ISG15 and UbcH8 gene knocked-down approach, our recent published and unpublished results explicitly demonstrated that the ISG15 pathway inhibits the ubiquitin-mediated proteasome-dependent protein degradation in breast cancer cells. We were the first to recognize this antagonizing effect of ISG15 in cancer cells.”

“Disruption of cellular architecture is a hallmark of cancer,” said Dr. Desai. “The ISG15 pathway is also elevated in a variety of tumors. Our results therefore reveal that the ISG15 pathway, which is aberrantly elevated in tumors could disrupt cell architecture and contribute to breast cancer cell motility. Because the cellular architecture is conserved and the ISG15 pathway is constitutively activated in tumor cells of different lineages, our observations in breast cancer must hold true for many other tumors.”

Related Links:

Louisiana State University School of Medicine




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.